That makes this more of a biotech company than a pot startup. And when you’re looking for a publicly traded investment to way the evolving regulatory and legal landscape around marijuana, you definitely want to look at a company like GW because of its experienced management.
Right now, the company is unprofitable – like many biotechs are – as it only has one marketed product. Specifically, its Sativex marijuana-based treatment for multiple sclerosis has been approved outside the U.S. However, the big mover in the near-term will be Epidiolex, a next-generation medical marijuana solution that is in late-stage testing and could launch in the U.S. next year.
Recreational marijuana is still having its moment at the ballot box, but medical marijuana is a much softer sell – and a big growth industry. GW Pharmaceuticals is perfectly positioned to profit from the near-term trends without the based on any unexpected “no” votes or setbacks on recreational drug use, and will undoubtedly have the necessary experience cutting through red tape to succeed in the growing marijuana space.
If you want a legit low-risk way to play the marijuana megatrend, GW is your best bet.